Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study
- PMID: 22905130
- PMCID: PMC3414465
- DOI: 10.1371/journal.pone.0042421
Personality, psychopathology, life attitudes and neuropsychological performance among ritual users of Ayahuasca: a longitudinal study
Abstract
Ayahuasca is an Amazonian psychoactive plant beverage containing the serotonergic 5-HT(2A) agonist N,N-dimethyltryptamine (DMT) and monoamine oxidase-inhibiting alkaloids (harmine, harmaline and tetrahydroharmine) that render it orally active. Ayahuasca ingestion is a central feature in several Brazilian syncretic churches that have expanded their activities to urban Brazil, Europe and North America. Members of these groups typically ingest ayahuasca at least twice per month. Prior research has shown that acute ayahuasca increases blood flow in prefrontal and temporal brain regions and that it elicits intense modifications in thought processes, perception and emotion. However, regular ayahuasca use does not seem to induce the pattern of addiction-related problems that characterize drugs of abuse. To study the impact of repeated ayahuasca use on general psychological well-being, mental health and cognition, here we assessed personality, psychopathology, life attitudes and neuropsychological performance in regular ayahuasca users (n = 127) and controls (n = 115) at baseline and 1 year later. Controls were actively participating in non-ayahuasca religions. Users showed higher Reward Dependence and Self-Transcendence and lower Harm Avoidance and Self-Directedness. They scored significantly lower on all psychopathology measures, showed better performance on the Stroop test, the Wisconsin Card Sorting Test and the Letter-Number Sequencing task from the WAIS-III, and better scores on the Frontal Systems Behavior Scale. Analysis of life attitudes showed higher scores on the Spiritual Orientation Inventory, the Purpose in Life Test and the Psychosocial Well-Being test. Despite the lower number of participants available at follow-up, overall differences with controls were maintained one year later. In conclusion, we found no evidence of psychological maladjustment, mental health deterioration or cognitive impairment in the ayahuasca-using group.
Conflict of interest statement
Similar articles
-
Assessment of addiction severity among ritual users of ayahuasca.Drug Alcohol Depend. 2010 Oct 1;111(3):257-61. doi: 10.1016/j.drugalcdep.2010.03.024. Epub 2010 Jun 15. Drug Alcohol Depend. 2010. PMID: 20554400
-
Personality Traits in Former Spanish Substance Users Recovered with Ayahuasca.J Psychoactive Drugs. 2020 Jul-Aug;52(3):264-272. doi: 10.1080/02791072.2020.1752960. Epub 2020 May 2. J Psychoactive Drugs. 2020. PMID: 32362241
-
Chemical Composition of Traditional and Analog Ayahuasca.J Psychoactive Drugs. 2021 Jan-Mar;53(1):65-75. doi: 10.1080/02791072.2020.1815911. Epub 2020 Sep 8. J Psychoactive Drugs. 2021. PMID: 32896230
-
Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact.Pharmaceuticals (Basel). 2020 Oct 23;13(11):334. doi: 10.3390/ph13110334. Pharmaceuticals (Basel). 2020. PMID: 33114119 Free PMC article. Review.
-
Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.Curr Neuropharmacol. 2019;17(2):108-128. doi: 10.2174/1570159X16666180125095902. Curr Neuropharmacol. 2019. PMID: 29366418 Free PMC article. Review.
Cited by
-
Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center.Front Pharmacol. 2021 May 19;12:659644. doi: 10.3389/fphar.2021.659644. eCollection 2021. Front Pharmacol. 2021. PMID: 34093190 Free PMC article.
-
Therapeutic potential of ayahuasca in grief: a prospective, observational study.Psychopharmacology (Berl). 2020 Apr;237(4):1171-1182. doi: 10.1007/s00213-019-05446-2. Epub 2020 Jan 14. Psychopharmacology (Berl). 2020. PMID: 31938878 Free PMC article. Clinical Trial.
-
Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents.ACS Chem Neurosci. 2019 Jul 17;10(7):3261-3270. doi: 10.1021/acschemneuro.8b00692. Epub 2019 Mar 4. ACS Chem Neurosci. 2019. PMID: 30829033 Free PMC article.
-
Psychedelic Microdosing: Prevalence and Subjective Effects.J Psychoactive Drugs. 2020 Apr-Jun;52(2):113-122. doi: 10.1080/02791072.2020.1718250. Epub 2020 Jan 23. J Psychoactive Drugs. 2020. PMID: 31973684 Free PMC article.
-
Psychedelics.Pharmacol Rev. 2016 Apr;68(2):264-355. doi: 10.1124/pr.115.011478. Pharmacol Rev. 2016. PMID: 26841800 Free PMC article. Review.
References
-
- Schultes RE, Hofmann A (1979) Plants of the Gods: Origins of hallucinogenic use. New York: McGraw-Hill. 192 p.
-
- Tupper KW (2008) The globalization of ayahuasca: Harm reduction or benefit maximization? Int J Drug Policy 19: 297–303. - PubMed
-
- Labate BC, Santana I, Santos RG (2008) Ayahuasca religions. A comprehensive bibliography & critical essays. Santa Cruz, CA: MAPS. 160 p.
-
- Instituto Nacional de Cultura, Perú (2008) Declaración Patrimonio Cultural de la nación a los conocimientos y usos tradicionales del Ayahuasca practicados por comunidades nativas amazónicas. RESOLUCIÓN DIRECTORAL NACIONAL N° 836/INC.
-
- McKenna DJ (2004) Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther 102: 111–129. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
